Skip to main content

Merck Value Stock - Dividend - Research Selection

Merck & Co Inc

ISIN: US58933Y1055, WKN: A0YD8Q

Market price date: 05.08.2022
Market price: 87,41 USD

Merck & Co Inc Fundamental data and company key figures of the share

Annual reports in USD
Key figures 14-03-2022
Cash flow
Net operating cash flow
Capital Expenditures -4.448.000.000
Free cash flow 8.673.999.872
Balance sheet
Total Equity
Liabilities & Shareholders equity 105.694.000.000
Income statement
Net income
Eps (diluted) 5,140
Diluted shares outstanding 2.530.230.000
Net sales/revenue 48.704.000.000

Fundamental ratios calculated on: 05-08-2022

Key figures 05-08-2022
Cash flow
P/C 16,86
P/FC 25,50
Balance sheet
Income statement
Div. Yield3,02%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization221.167.403.008,00 USD
CountryUnited States
IndicesDow Jones Industrial Average,MSCI World Index,S&P 500
Raw Data SourceUS GAAP in Millionen USD
Stock Split2021-06-03,1048.000000/1000.000000; 1999-02-17,2.0000/1.0000; 1997-06-04,1.000000/1.000000; 1995-06-12,1.000000/1.000000; 1992-05-26,3.0000/1.0000; 1988-05-26,3.0000/1.0000; 1986-05-27,2.0000/1.0000; 1972-06-01,2.0000/1.0000

Description of the company

Merck & Co., Inc. (Merck) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company consists of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment, which is the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Effective February 25, 2013, Dashtag, a unit of Merck & Co Inc's Schering Plough Corp subsidiary acquired 17.95% interest in Fulford (India) Ltd.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


5 Relatively Safe And Cheap Dividend Stocks To Invest In - August 2022

It's always a good idea to keep your wish list ready by separating the wheat from the chaff. Check out 3 groups of 5 stocks each to suit your investment needs.

3 Great Stocks to Buy in August for Safety and Long-Term Growth

The episode focuses on three stocks--Humana, Merck, and Dollar Tree--that have proven they can climb during 2022's falling market and operate businesses that are likely to withstand any economic downturn or possible recession.

Myriad Genetics (MYGN) Q2 Earnings Top, Gross Margin Down

Myriad Genetics (MYGN) posts better-than-expected results in Q2 with contributions from most product lines.

How We're Supporting the Advancement of Women of Color at Our Company

We joined forces with Paradigm for Parity to help build skills and capabilities needed for senior leadership roles

Pharmaceutical CEOs use earnings calls to criticize drug-pricing proposal

Executives at AbbVie, J&J, and Merck say the suggested changes in their current form would be 'chilling' or 'detrimental' to the development of new therapies.

UK shareholder meetings calendar - next 7 days

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Merck - LYNPARZA (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer

RAHWAY, N.J. - AstraZeneca and Merck , known as MSD outside the United States and Canada, announced that the European Commission has approved LYNPARZA as monotherapy or in combination with endocrine... | August 5, 2022

MERCK & CO., INC. Management's Discussion and Analysis of Financial Condition and Resultsof Operations (form 10-Q)

Business DevelopmentsBelow is a summary of significant business development activity thus far in2022. See Note 3 to the condensed consolidated financial statements foradditional information.In... | August 5, 2022

August Dogs Of The Dow Show 4 To Buy + One To Watch

While more than half this collection of Dow Industrials is too pricey, four of the five lowest-priced Dogs of the Dow stocks are ready to buy.

12 Best Healthcare Stocks To Buy Now

In this piece, we will take a look at the twelve best healthcare stocks to buy now. If you want to skip the details and head on to the top stocks in this list, then take a look at 5 Best Healthcare Stocks To Buy Now. Healthcare stocks are proving to be resilient in the […]